The Fibroblast Growth Factor Receptors in Breast Cancer: from Oncogenesis to Better Treatments
1
Section of Epidemiology and Population Science, Department of Medicine, Baylor College of Medicine, 1 Baylor Plaza, Houston, TX 77030, USA
2
Department of Medical, Surgical and Health Sciences, University of Trieste, Cattinara Hospital, Strada Di Fiume 447, 34149 Trieste, Italy
*
Authors to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(6), 2011; https://doi.org/10.3390/ijms21062011
Received: 24 February 2020 / Revised: 11 March 2020 / Accepted: 14 March 2020 / Published: 16 March 2020
(This article belongs to the Special Issue FGF/FGFR Signaling Pathway in Development and Human Diseases)
Breast cancer (BC) is the most frequent form of malignancy and second only to lung cancer as cause of deaths in women. Notwithstanding many progresses made in the field, metastatic BC has a very poor prognosis. As therapies are becoming more personalized to meet the needs of patients, a better knowledge of the molecular biology leading to the disease unfolds the possibility to project more precise compounds or antibodies targeting definite alteration at the molecular level and functioning on such cancer-causing molecules expressed in cancer cells of patients, or present as antigens on the surface of cancer cell membranes. Fibroblast growth factor receptor (FGFR) is one of such druggable targets, activated by its own ligands -namely the Fibroblast Growth Factors (FGFs). This pathway provides a vast range of interesting molecular targets pursued at different levels of clinical investigation. Herein we provide an update on the knowledge of genetic alterations of the receptors in breast cancer, their role in tumorigenesis and the most recent drugs against this particular receptor for the treatment of the disease.
View Full-Text
▼
Show Figures
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
MDPI and ACS Style
Sobhani, N.; Fan, C.; O. Flores-Villanueva, P.; Generali, D.; Li, Y. The Fibroblast Growth Factor Receptors in Breast Cancer: from Oncogenesis to Better Treatments. Int. J. Mol. Sci. 2020, 21, 2011.
AMA Style
Sobhani N, Fan C, O. Flores-Villanueva P, Generali D, Li Y. The Fibroblast Growth Factor Receptors in Breast Cancer: from Oncogenesis to Better Treatments. International Journal of Molecular Sciences. 2020; 21(6):2011.
Chicago/Turabian StyleSobhani, Navid; Fan, Chunmei; O. Flores-Villanueva, Pedro; Generali, Daniele; Li, Yong. 2020. "The Fibroblast Growth Factor Receptors in Breast Cancer: from Oncogenesis to Better Treatments" Int. J. Mol. Sci. 21, no. 6: 2011.
Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
Search more from Scilit